echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Cinda introduces next-generation PDE4 inhibitors for 267 million yuan to treat inflammatory skin diseases

    Cinda introduces next-generation PDE4 inhibitors for 267 million yuan to treat inflammatory skin diseases

    • Last Update: 2021-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    On September 28, Innovent announced that with UNION therapeutics, UNION’s main drug candidate for the treatment of inflammatory skin diseases, orismilast, a potential best-in-class PDE4 inhibitor in clinical phase II, has reached an agreement in China (including mainland China).


    According to the terms of the agreement, Cinda Bio will obtain the exclusive rights to research, development and commercialization of orismilast in China


    Orismilast is a potent and highly selective next-generation PDE4 inhibitor with a wide range of anti-inflammatory properties


    Based on orsimilast, UNION has two product candidates in clinical phase II development


    There are approximately 50 million patients with atopic dermatitis and 6 million patients with psoriasis in China, and the incidence is showing a gradual increase with changes in life>


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.